Video
Dr. Greten on Promising Immunotherapy Agents in HCC
Author(s):
Tim F. Greten, MD, senior investigator thoracic and gastrointestinal oncology branch, head, gastrointestinal malignancy section, National Cancer Institute, discusses promising immunotherapy agents being investigated in hepatocellular carcinoma (HCC).
Tim F. Greten, MD, senior investigator thoracic and gastrointestinal oncology branch, head, gastrointestinal malignancy section, National Cancer Institute, discusses promising immunotherapy agents being investigated in hepatocellular carcinoma (HCC).
The immunotherapy that is furthest developed in this space is nivolumab (Opdivo), which is being investigated in a phase III study, explains Greten.
,br>Additionally, cell-based therapies are being looked at but they are harder to investigate as there are very little data to analyze, states Greten.
Chimeric antigen receptor (CAR) T-cell therapy has not been very successful in solid cancers but it is 1 of the future areas that will be studied for patients with HCC.
